Regeneron Pharmaceuticals (REGN)
(Delayed Data from NSDQ)
$651.80 USD
-2.24 (-0.34%)
Updated Oct 31, 2025 04:00 PM ET
After-Market: $650.60 -1.20 (-0.18%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth A Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, Regeneron Pharmaceuticals, Inc. has a PEG ratio of 1.45 compared to the Medical - Biomedical and Genetics industry's PEG ratio of 1.58.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
REGN 651.80 -2.24(-0.34%)
Will REGN be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for REGN based on the 1-3 month trading system that more than doubles the S&P 500.

Zacks News for REGN
REGN Stock Up on Q3 Earnings Beat, Eylea HD Sales Increase
Compared to Estimates, Regeneron (REGN) Q3 Earnings: A Look at Key Metrics
REGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Regeneron (REGN) Q3 Earnings and Revenues Surpass Estimates
Sanofi Q3 Earnings Beat, Dupixent Drives Growth as Vaccines Decline
REGN Q3 Earnings: Will Higher Dupixent Profits Offset Eylea Sales Decline?
Other News for REGN
Insider Moves: Blackstone, Regeneron, Schwab, Celestica, Corning
REGN forms Upper Bollinger Band Walk on October 31
Director’s Bold Move: Regeneron Stock Sale Shakes Up the Market!
Investor Michael Burry Warns Of Market Bubble
Upper Bollinger Band Walk appears for REGN after 0.17% move